Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma

CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(01): 082-083
DOI: 10.1055/s-0041-1731911

Case Report

Authors

Sanju Cyriac

¹Department of Medical Oncology, Rajagiri Hospital, Kochi, Kerala, India
Ajith Toms

²Department of Radiology, Rajagiri Hospital, Kochi, Kerala, India
Sunitha Thomas

³Department of Pathology, Rajagiri Hospital, Kochi, Kerala, India

References
1 Tsur N, Kogan Y, Avizov-Khodak E. et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med 2019; 17 (01) 338
2 Burns MC, O'Donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016; 4 (08) 867-873
3 Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med 2016; 4 (14) 269
4 Robert C, Ribas A, Hamid O. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018; 36 (17) 1668-1674
5 Cancer Research Institute. Immunotherapy for Melanoma. Accessed August 20, 2020 at: https://www.cancerresearch.org/immunotherapy/cancer-types/melanoma